Daily Stock Analysis, COLL, Collegium Pharmaceutical Inc, priceseries

Collegium Pharmaceutical Inc. Daily Stock Analysis
Stock Information
Open
17.29
Close
17.43
High
17.72
Low
17.07
Previous Close
17.30
Daily Price Gain
0.13
YTD High
20.92
YTD High Date
Dec 5, 2017
YTD Low
7.37
YTD Low Date
May 9, 2017
YTD Price Change
1.75
YTD Gain
11.16%
52 Week High
20.92
52 Week High Date
Dec 5, 2017
52 Week Low
7.37
52 Week Low Date
May 9, 2017
52 Week Price Change
0.20
52 Week Gain
1.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 9. 2017
12.71
Nov 27. 2017
15.16
11 Trading Days
19.24%
Link
Company Information
Stock Symbol
COLL
Exchange
NasdaqGS
Company URL
http://www.collegiumpharma.com
Company Phone
781-713-3699
CEO
Michael Thomas Heffernan
Headquarters
Massachusetts
Business Address
780 DEDHAM STREET, SUITE 800, CANTON, MA 02021
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001267565
About

Collegium Pharmaceutical, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products. These products target market opportunities through formulation based product improvements protected by intellectual property. It builds a portfolio of pain products that incorporate its patent protected DETERx formulation platform that provides for extended release and tamper resistance. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Canton, MA.

Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. The company also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.